Modulating T cell Metabolism – From a Type I Kinase Inhibitor to an Oral Heterobifunctional Kinase Degrader
Time: 3:30 pm
day: Day Two
Details:
- Starting from an efficacious in vitro / in vivo active type I kinase inhibitor
- Degrading the kinase instead of blocking it has the same in vitro cellular effects on primary T cell metabolism
- Optimizing a kinase inhibitor into an oral bifunctional degrader for in vivo use
